Side-by-side comparison of AI visibility scores, market position, and capabilities
AI pharma drug launch platform compressing market access research from months to minutes; six-figure ARR within weeks of launch with Bayer as client across 12 markets.
Cellbyte is an AI-powered pharmaceutical drug launch platform that accelerates global drug launches by providing real-time pricing and market access intelligence — compressing processes that traditionally take months or years (reference pricing analysis, health technology assessment research, payer landscape mapping) into minutes using AI-driven data aggregation and analysis. Founded in 2024 and a Y Combinator graduate, Cellbyte raised $2.75 million in seed funding led by Frontline Ventures and Y Combinator, achieving six-figure ARR within weeks of launch.\n\nCellbyte's platform aggregates regulatory approval data, drug pricing reference lists, payer coverage policies, and health technology assessment outcomes across multiple countries to help pharmaceutical market access teams make faster, better-informed launch sequence decisions. Global drug launches require navigating distinct pricing and reimbursement systems in each country — reference pricing (where one country's price affects another's) makes launch sequencing strategically critical and data-intensive. Cellbyte automates the research that market access consultants previously performed manually.\n\nIn 2025, Cellbyte secured major clients including Bayer across 12 live markets — demonstrating enterprise adoption velocity unusual for a seed-stage company. The pharmaceutical market access software market includes specialized players like IQVIA (market data), ZS Associates (consulting), and early-stage AI entrants. The total addressable market is substantial given the global pharmaceutical market's hundreds of billions in annual drug launches. Cellbyte's 2025-2026 strategy focuses on expanding the breadth of markets covered (targeting all major pharma markets globally), deepening AI capabilities for predictive pricing modeling, and growing its pharmaceutical client base beyond the initial anchor customers.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.